Northwest Biotherapeutics provides update on final preparations for MAA

Northwest Biotherapeutics provided an update about the final preparations for the Marketing Authorization Application that will be submitted to the Medicines and Healthcare Products Regulatory Agency in the U.K. for commercial approval of the Company’s DCVax-L treatment for glioblastoma. The Company previously reported that one key section of the MAA package remained to be completed and to then be delivered to an independent publisher for quality control checking of citations, numbers, cross-references, formatting and the like, in preparation for the submission. The Company provided an update that most of the work has been completed on the key section of the MAA that remained to be done at the time of the prior update, as well as on required supporting documents, the majority of which have been delivered to the publisher/QC team. That team is now under way on this final stage of their work. As described in the Company’s prior update, it is anticipated that the publisher/QC team will need several weeks to complete their work on both the last portion of the MAA package and the integrated whole. Their work is independent of the Company.